WDR4 can negatively regulate PML via ubiquitination to drive lung tumour development by fostering the development of an immune-suppressive and premetastatic tumour microenvironment, indicating the potential of immune-modulatory methods for treating lung carcinoma [18]. This evidence concerns the gene WDR4 and neoplasm.